At the recent International Summit on Diabetes and COVID-19 (co-hosted by Sansum Diabetes Research Institute https://www.diabetestechnology.org/cds/agenda.shtml), there was some good news in the fight against the COVID-19 pandemic. There are 138 vaccines in development and 30 have progressed to clinical trials. Although we do not know exactly when the first one will become available, there are plans to offer new vaccines to certain groups of people. The first available vaccines will be offered to frontline healthcare workers and first responders, according to recommendations from the National Academies of Sciences, Engineering, and Medicine (NASEM). Next in line will be people of any age living with two or more underlying conditions with the highest risk of severe outcomes from COVID-19, along with older adults living in long-term care facilities. This group includes people with type 2 diabetes and obesity. The next phase includes critical workers at high risk for exposure (including meat processing workers, grocery store workers, etc.), along with teachers and school staff, older adults missed during the initial phase, and individuals with underlying conditions at moderately higher risk of poor outcomes. Residents and employees of homeless shelters, group homes, prisons, jails, and detention facilities would also be included. While Black, Hispanic, and American Indian and Alaska Native communities have been hit hard by COVID-19, the guidance does not specifically prioritize these populations for earlier vaccination.
Photo by Rawpixel